The Potential of Antibodies Against the Phosphatidylserine / Prothrombin Complex as a Biomarker in Antiphospholipid Syndrome
DOI:
https://doi.org/10.12775/JEHS.2025.78.57631Keywords
Antiphospholipid syndrome, Anti-phosphatidylserine/prothrombin complex antibodies, Systemic Lupus Erythematosus, Lupus anticoagulant, ThrombosisAbstract
Introduction
Antibodies against the phosphatidylserine/prothrombin complex aPS/PT are autoantibodies recognizing an epitope formed in the phosphatidylserine/prothrombin complex as a result of conformational changes resulting from the combination and not present in any of the initial components of the complex. Its presence is predominantly observed in patients with thrombotic complications, particularly in those suffering from antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE), and other connective tissue disorders. The new epitope is clinically relevant, as it plays a role in the mechanism and effects of autoantibody binding to phospholipids and their cofactors. Testing for aPS/PT, in conjunction with other APS markers, is recommended to assess the risk of thrombotic events.
Purpose
The object of this review is to assess whether aPS/PT complex serves as an effective diagnostic marker in the pathogenesis of complications associated with APS and other connective tissue disorders.
Material and methods
This review evaluates data from medical databases such as PubMed, NCBI or BMJ using the search term ‘aPS/PT’.
Conclusion
The presence of aPS/PT may be considered an independent risk factor for thrombosis. However, further research is needed to fully validate its clinical relevance in various clinical scenarios.
References
Arad A, Prouille V, Furie RA, Furie BC, Furie B. beta-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood. 2011;117(12):3453–9. doi: 10.1182/blood-2010-08-300715.
Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum.2000;43(9): 1982–1993.
Bardin N, Alessi MC, Dignat-George F, et al. Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis? Immunobiology 2007;212(7):557–565.
P Bermudez-Bermejo, G Hernandez-Molina, DF Hernandez-Ramirez, V Zamora-Legoff, E Olivares-Martínez, AR Cabral, CA Núñez-Alvarez, FRI0292 Anti-phosphatidylserine/prothrombin (APS/PT) antibodies in primary antiphospholipid syndrome
Bertolaccini ML, Atsumi T, Koike T, Hughes GR, Khamashta MA. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost.2005;93(2):289–297
Bizzaro N, Ghirardello A, Zampieri S, et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost.2007;5(6):1158–1164.
Branch DW, Andres R, Digre KB, Rote NS, Scott JR. The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol. 1989;73(4):541–5.
Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–27. doi: 10.1002/art.10187.
Clark CA, Davidovits J, Spitzer KA, Laskin CA. The lupus anticoagulant: results from 2257 patients attending a high-risk pregnancy clinic. Blood. 2013;122(3):341–347. doi: 10.1182/blood-2013-02-485839. quiz 466.
Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, Duarte-García A. Epidemiology of Antiphospholipid Syndrome in the General Population. Curr Rheumatol Rep. 2022 Jan 05;23(12):85.
Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. doi: 10.1136/bmj.315.7109.629.
Ganapati A, Goel R, Kabeerdoss J, et al. Study of clinical utility of antibodies to phosphatidylserine/prothrombin complex in Asian-Indian patients with suspected APS. Clin Rheumatol. 2019;38(2):545–553.
Grygiel-Górniak B, Mazurkiewicz Ł. Positive antiphospholipid antibodies: observation or treatment? J Thromb Thrombolysis. 2023 Aug;56(2):301-314.
Heikal NM, Jaskowski TD, Malmberg E, et al. Laboratory evaluation of anti-phospholipid syndrome: a preliminary prospective study of phosphatidylserine/prothrombin antibodies in an at-risk patient cohort. Clin Exp Immunol.2015;180(2):218–226.
Ariela Hoxha, Amelia Ruffatti, Elena Mattia, Lauro Meneghel, Marta Tonello, Elisa Salvan,VittorioPengo, Leonardo Punzi Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome 2015 Jul;53(8):1265-70. doi: 10.1515/cclm-2014-1129 PMID: 25562605
Hoxha A, Mattia E, Tonello M, Grava C, Pengo V, Ruffatti A. Anti Phosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. Clin Chem Lab Med. 2017;55(6):890–8.
Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. Ann Rheum Dis. 2003;62(12):1127.
Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ. 2023 Feb 27;380:e069717.
Lazurova I, Macejova Z, Tomkova Z, Remenar F, Boor A, Lazur J, et al. Severe limb necrosis: primary thrombotic microangiopathy or “seronegative” catastrophic antiphospholipid syndrome? A diagnostic dilemma. Clin Rheumatol. 2007;26(10):1737–40.
Litvinova E, Darnige L, Kirilovsky A, et al. Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria. Front Immunol.2018;9:2971.
Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012;64(7):2311–2318. doi: 10.1002/art.34402.
Losonczy LI, Johnson B, Sidhu J, Li J, Feeney CM. Seronegative catastrophic antiphospholipid syndrome in a young female presenting with a headache. J Emerg Med. 2015;48(3):294–7.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostasis. 2006;4(2):295–306.
Carlos A Núñez-Álvarez, Gabriela Hernández-Molina, Paola Bermúdez-Bermejo, Victor Zamora-Legoff, Diego F Hernández-Ramírez, Elizabeth Olivares-Martínez, Antonio R Cabral Prevalence and associations of anti-phosphatidylserine/prothrombin antibodies with clinical phenotypes in patients with primary antiphospholipid syndrome: aPS/PT antibodies in primary antiphospholipid syndrome 2019 Feb:174:141-147. doi: 10.1016/j.thromres.2018.12.023. Epub 2018 Dec 29. PMID: 30612005
Pasquale Pignatelli, Evaristo Ettorre, Danilo Menichelli, Arianna Pani, Francesco Violi, Daniele Pastori, Seronegative antiphospholipid syndrome: refining the value of “non-criteria” antibodies for diagnosis and clinical management 2020 Jan 30;105(3):562–572. doi: 10.3324/haematol.2019.221945 PMCID: PMC7049333 PMID: 32001534
Elena Pontara, Maria Grazia Cattini, Chunyan Cheng, Elisa Bison, Gentian Denas, Vittorio Pengo Insight into the hypercoagulable state of high-risk thrombotic APS patients: Contribution of aβ2GPI and aPS/PT antibodies Affiliations expand 2021 Mar;19(3):805-813. doi: 10.1111/jth.15199. Epub 2020 Dec 25. PMID: 33249717
Rodriguez-Garcia JL, Bertolaccini ML, Cuadrado MJ, Sanna G, Ateka-Barrutia O, Khamashta MA. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ‘seronegative APS’). Ann Rheum Dis. 2012;71(2):242–4.
Abdulrahman Saadalla, Vijaya Nadakumar Anti-phosphatidyl-serine/prothrombin (aPS/PT) antibodies are superior predictors of LAC presence and APS diagnoses: A single center study. 2021 Jul;30(8):1289-1299. doi: 10.1177/09612033211014570. Epub 2021 May 6.
Sciascia S, Sanna G, Murru V, et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost.2014;111(2):354–364.
Hui Shi, Hui Zheng, Yu-Feng Yin, Qiong-Yi Hu, Jia-Lin Teng, Yue Sun, Hong-Lei Liu, Xiao-Bing Cheng, Jun-Na Ye, Yu-Tong Su, Xin-Yao Wu, Jin-Feng Zhou, Gary L Norman, Hui-Yun Gong, Xin-Ming Shi, Yi-Bing Peng, Xue-Feng Wang, Cheng-De Yang Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome 2018 Mar 28;56(4):614-624. doi: 10.1515/cclm-2017-0502. PMID: 29166262
Tonello M, Mattia E, Favaro M, et al. IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. Thromb Res.2019;177:157–160.
Wilson WA, Gharavi AE, Koike T, Lockshin MD, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheumatol. 1999;42(7):1309–11.
Vaarala O, Puurunen M, Mänttäri M, et al. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost.1996;75(3):456–459.
Shulan Zhang, Ziyan Wu, Wen Zhang, Jiuliang Zhao, Gary L Norman, Xiaofeng Zeng, Fengchun Zhang, Yongzhe Li, Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome 2018 May 24;56(6):939-946. doi: 10.1515/cclm-2017-0811. PMID: 29561729
Rui Zhu, Chun-Yan Cheng, Yan Yang, Gentian Denas, Vittorio Pengo Prevalence of aPhosphatidylserine/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: A systematic review and meta-analysis 2022 Jun:214:106-114. doi: 10.1016/j.thromres.2022.04.021.Epub 2022 May 2. PMID: 35526513
Zigon P, Perdan Pirkmajer K, Tomsic M, et al. Anti-Phosphatidylserine/Prothrombin Antibodies Are Associated with Adverse Pregnancy Outcomes. J Immunol Res.2015;2015:975704.
Zigon P, Podovsovnik A, Ambrozic A, et al. Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements. Clin Rheumatol.2019;38(2):371–378.
P. Žigon, A. Ambrožič, M. Tomšič, S.S. Šemrl, S. Čučnik SAT 0418 IGA Anti-Phosphatidylserine/Prothrombin Antibodies Present a Thrombotic Risk in Patients with Systemic Autoimmune Diseases
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Piotr Pasek, Witold Czyż, Julia Kulbacka, Julia Kacperczyk, Marta Chuncia-Ileczko, Michalina Wójcikiewicz, Filip Arczewski, Karol Dziedzic, Maciej Wojszczyk, Damian Zys, Julia Ryniecka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 485
Number of citations: 0
